NOVOMEDLINK™
  1. Activella®

    (estradiol/norethindrone acetate tablets)

  2. Vagifem®

    (estradiol vaginal tablets)

  3. GlucaGen® HypoKit®

    (glucagon [rDNA Origin] for injection)

  4. Levemir®

    (insulin detemir [rDNA origin] injection)

  5. Norditropin®

    (somatropin (rDNA origin) injection)

  6. NovoLog®

    (Insulin aspart [rDNA origin] injection)

  7. NovoLog® Mix 70/30

    (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin])

  8. NovoSeven® RT

    Coagulation Factor VIIa (Recombinant) Room
    Temperature Stable

  9. NovoSeven®

    (Coagulation Factor VIIa [Recombinant])

patient resources

NovoSeven® RT Resources


SevenSTART

SevenSTART is an experience program that provides a free trial of NovoSeven® RT to hemophilia A and B patients with inhibitors to FVIII or FIX who are not currently using NovoSeven® RT as their primary, on-demand treatment for bleeding. This experience program is a one-time-only trial that will enable patients to see if NovoSeven® RT treatment is right for them.

To enroll your patients, contact your Novo Nordisk sales manager or call 877-NOVO-777 (877- 668-6777).

Physician's Sample Travel Letter

Are your patients traveling? If so, you may wish to offer them a travel letter to pass through security with the therapy. Download the sample travel letter template.

Ready to Travel Case

The Ready to Travel case is an easy way to store supplies for travel. To get a Ready to Travel case, call 1-877-NOVO-777 (877-668-6777).

Infusion Kit

The infusion kit, which is supplied separately from the NovoSeven® RT kit, contains supplies to reconstitute and infuse NovoSeven® RT. To order infusion kits for your patients, call 1-877-668-6777.

NovoSevenRT.com

This website is a comprehensive resource to help your patients learn about their bleeding disorder and treatment options. Extensive information helps patients implement treatment effectively and enjoy the added conveniences of NovoSeven® RT.

Voices Uninhibited Newsletter

This publication from Novo Nordisk is all about living with inhibitors. It is filled with inspiring interviews, useful medical information, and real-life tips. Encourage your patients to join the mailing list. Call 1-877-668-6777 or email voices@novonordisk.com.

NovoSevenRT® Question and Answer Guide

This questions and answer guide will lead your patients through the new room temperature formulation. To order the Question and Answer Guide for your patients, please contact your Novo Nordisk Representative or call 1-877-668-6777.

Educational Resources


Educational Brochure series

Novo Nordisk offers a series of brochures written by people with inhibitors for people with inhibitors. Call 1-877-668-6777 to request the brochures.

MyInhibitor.org

This educational website offers detailed information for people with inhibitors on important topics such as joint health, surgical options, and social issues. Brought to you by Novo Nordisk.

Community Talks on Rare Bleeding Disorders

Your patients can get access to the latest information through the Community Talks on Rare Bleeding Disorders program. Sponsored by Novo Nordisk and presented by well-respected hemophilia health care providers, these talks are engaging, educational events. For more information, call 1-877-NOVO-777 (1-877-668-6777).

Associations


National Hemophilia Foundation (NHF) This link will take you to a website outside of Novo Nordisk's network of product websites.

The NHF is dedicated to finding better treatments and cures for bleeding and clotting disorders and to preventing the complications of these disorders through education, advocacy, and research.

Hemophilia Federation of America (HFA) This link will take you to a website outside of Novo Nordisk's network of product websites.

The HFA is a national 501(c)(3) organization with a mission of assistance, education, and advocating for the hemophilia community.

World Federation of Hemophilia (WFH) This link will take you to a website outside of Novo Nordisk's network of product websites.

An extensive website with information about international developments in the advancement of hemophilia care.

American Society of Pediatric Hematology/Oncology (ASPH/O) This link will take you to a website outside of Novo Nordisk's network of product websites.

The Society serves both medical professionals and patients. It is dedicated to advancing knowledge in pediatric blood diseases and cancer.

International Society on Thrombosis and Haemostasis This link will take you to a website outside of Novo Nordisk's network of product websites.

The ISTH is a membership association that supports a nonprofit mission of education and stimulation of research through meetings, peer-reviewed publications, and expert committees.

Centers for Disease Control and Prevention (CDC) This link will take you to a website outside of Novo Nordisk's network of product websites.

An agency of the US Department of Health and Human Services (HHS), the CDC focuses on preventing and controlling disease, injury, and disability.

Hemophilia Treatment Centers This link will take you to a website outside of Novo Nordisk's network of product websites.

The CDC maintains a complete listing of HTCs in the U.S.

Hemophilia & Thrombosis Research Society This link will take you to a website outside of Novo Nordisk's network of product websites.

HTRS is dedicated to advancing the care of persons with bleeding or clotting disorders through clinical research, professional mentoring, and continuing medical education.

American Thrombosis & Hemostasis Network This link will take you to a website outside of Novo Nordisk's network of product websites.

ATHN is a non-profit organization founded to advance and improve the care of individuals affected by bleeding and thrombotic disorders.

  1. NovoSeven® RT Coagulation Factor VIIa (Recombinant) Room Temperature Stable Indications and Usage

    NovoSeven® RT is indicated for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to FVIII or FIX and in patients with acquired hemophilia; prevention of bleeding in surgical interventions or invasive procedures in hemophilia A or B patients with inhibitors to FVIII or FIX and in patients with acquired hemophilia; treatment of bleeding episodes in patients with congenital Factor VII deficiency and prevention of bleeding in surgical interventions or invasive procedures in patients with congenital FVII deficiency.

    NovoSeven® RT Important Safety Information

    • Most common adverse events: pyrexia, hemorrhage, injection site reaction, arthralgia, headache, hypertension, hypotension, nausea, vomiting, pain, edema, and rash.
    • Patients with disseminated intravascular coagulation (DIC), advanced atherosclerotic disease, crush injury, septicemia, or concomitant treatment with activated or nonactivated prothrombin complex concentrates (aPCCs/PCCs) may have a potential risk of developing thrombotic events in association with NovoSeven® treatment.
    • Use with caution in patients with known hypersensitivity to NovoSeven®, its components, or mouse, hamster, or bovine proteins.
    • Serious adverse events that may or may not have been related to the use of NovoSeven® in acquired hemophilia (10 of 139 patients in the compassionate use program, HTRS registry, and the published literature) included thrombotic serious adverse events and death.
    • Serious adverse events that may or may not have been related to the use of NovoSeven® occurred in 14 of 298 patients with hemophilia A or B with inhibitors in the initial clinical program.
    • Development of antibodies against FVII has been reported in FVII-deficient patients after treatment with NovoSeven®. These patients had previously been treated with human plasma and/or plasma-derived FVII.
    • Concomitant use of NovoSeven® RT with other formulations of NovoSeven® is not recommended due to potential dosing errors based on different concentrations.
    • The effect of prolonged post-hemostatic dosing of NovoSeven® RT has not been extensively studied in a clinical setting.

    Please see Prescribing Information.

Levemir®, NovoLog®, NovoLog® Mix 70/30, GlucaGen®, and HypoKit® are registered trademarks of Novo Nordisk A/S. NovoSeven® RT and Norditropin® are registered trademark and SevenSECURE™ is a trademark of Novo Nordisk Health Care AG. Activella® 1.0 mg/0.5 mg and Activella® 0.5 mg/0.1 mg and Vagifem® are registered trademarks of Novo Nordisk FemCare AG.